Galectin Therapeutics Inc
GALT
Company Profile
Business description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact
4960 Peachtree Industrial Boulevard
Suite 240
NorcrossGA30071
USAT: +1 678 620-3186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
9
Stocks News & Analysis
stocks
Wide moat share remains cheap despite rising costs
Higher costs weigh on profits but stronger sales trends support long term outlook.
stocks
Fair value upgrade for ASX listed fast food chain
Earnings beat lifts forecasts but long term growth questions remain.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,374.90 | 50.40 | 0.54% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,489.35 | 72.19 | 0.14% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,511.10 | 6.23 | -0.02% |
| NASDAQ | 26,143.38 | 163.20 | 0.63% |
| Nikkei 225 | 65,856.43 | 328.34 | 0.50% |
| NZX 50 Index | 13,992.72 | 110.84 | 0.80% |
| S&P 500 | 7,675.40 | 22.54 | 0.29% |
| S&P/ASX 200 | 9,164.60 | 54.30 | 0.60% |
| SSE Composite Index | 3,889.44 | 7.44 | 0.19% |